Differences

Last edited on June 7, 2023

This shows you the differences between two versions of the page.

--- meds:dopamine-agonists:pramipexole [on September 15, 2018]
+++ meds:dopamine-agonists:pramipexole [on February 18, 2022]
psychdb [Side Effects]
@@ Line 1: / Line 1: @@
+====== Pramipexole ======
+{{INLINETOC}}
+===== Primer ====
+**Pramipexole** (Tradename: //Mirapex//) is a dopamine agonist used in the treatment of [[geri:parkinsons|]] and [[sleep:parasomnias:rls|restless legs syndrome]].
+==== Mechanism of Action ====
+  * It is a D2 receptor agonist and also has receptor selectivity for the D3 receptor subtype of the D2 subfamily of receptors.
+==== Side Effects ====
+  * There is the potential to cause compulsive behaviours and sudden sleep attacks.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC116443/|Homann, C. N., Wenzel, K., Suppan, K., Ivanic, G., Kriechbaum, N., Crevenna, R., & Ott, E. (2002). Sleep attacks in patients taking dopamine agonists. Bmj, 324(7352), 1483-1487.]])]
+  * Pramipexole has the highest risk for developing impulse control disorders, with an up to 40% incidence.[([[https://pubmed.ncbi.nlm.nih.gov/29925549/|Corvol, J. C., Artaud, F., Cormier-Dequaire, F., Rascol, O., Durif, F., Derkinderen, P., ... & DIGPD Study Group. (2018). Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology, 91(3), e189-e201.]])]
+===== Adverse Events =====
+==== Impulse-Control Disorders (ICDs) ====
+{{page>geri:parkinsons#impulse-control-disorders-icd&nouser&noheader&nodate&nofooter}}
+===== Resources =====
+  * [[https://pubmed.ncbi.nlm.nih.gov/30361297/|Martinez-Castrillo, J. C. (2019). Impulse control disorders in Parkinson’s disease: a hard-turning point. Journal of Neurology, Neurosurgery & Psychiatry, 90(1), 2-2.]]